This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Press and hold the button
If you believe this is an error, please contact our support team.
192.64.82.12 : 560f16d7-bb00-4411-ac0a-ace28892
Credit: Anna Shvets from Pexels Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research
Just a moment… Enable JavaScript and cookies to continue This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until
Graphical Abstract. Credit: European Heart Journal (2024). DOI: 10.1093/eurheartj/ehae596 A combined subgroup analysis of the similar trials NOAH—AFNET 6 and ARTESiA has revealed that patients with device-detected atrial fibrillation and
